Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025International Journal of NanomedicineOpen Access

Advances in Lipid-Based Nanomedicine: Pathway Specific siRNA Therapy and Optimizing Delivery for Hepatocellular Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

KTKarkaz M. ThalijHYHuay Woon YouKAKiran Balasaheb Aher

Discussion

Loading...

Member takes

Overview

Review explores siRNA therapy and nanoparticle delivery in hepatocellular carcinoma, highlighting innovations for effective treatment.

Key Points

  • siRNA therapy shows promise in silencing pathways critical for tumor progression, particularly in hepatocellular carcinoma.
  • Lipid-based nanoparticles enhance siRNA delivery and cellular uptake while ensuring safety and biocompatibility.
  • Advancements in targeting mechanisms, such as ApoE-mediated uptake, enable liver-specific delivery of siRNA.
  • AI plays a crucial role in optimizing siRNA design and formulation for personalized therapy advancements.

Cite This Study

Thalij et al. (2025) studied this question.

synapsesocial.com/papers/68c1d7f654b1d3bfb60fa101https://doi.org/10.2147/ijn.s532246
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lipid-based nanomedicine for hepatocellular carcinoma: flavonoid-enhanced, pathway-specific siRNA delivery strategies and clinical progress2026
  2. 2Lipid Nanoparticles as a Platform for miRNA and siRNA Delivery in Hepatocellular Carcinoma2024 · 10 citations
  3. 3Nanoscale Delivery Systems for Hepatocellular Carcinoma: Functionalization, Delivery Strategies, and Clinical Challenges2026 · 3 citations
  4. 4Recent advances in hepatocellular carcinoma-targeted nanoparticles2024 · 3 citations
  5. 5Emerging nanomedicine strategies for hepatocellular carcinoma therapy2024 · 2 citations